Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing news related to
Showing 1–1 of 1 stories
Recent research highlights the potential of RNA interference (RNAi) therapeutics in treating ATTR amyloidosis, showcasing advancements from laboratory studies to clinical applications. This innovative approach could significantly impact patient outcomes by targeting the underlying genetic causes of the disease.
Get the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.